Not checkedNot checked for notices yet.
Homeopathy for mental fatigue: lessons from a randomized, triple blind, placebo-controlled cross-over clinical trial
Dean Michael, Karsandas Raj, Bland J and 2 more
BMC Complementary and Alternative Medicine · 2012
doi:10.1186/1472-6882-12-167 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>Difficulty in controlling attention can lead to mental fatigue in the healthy population. We identified one trial reporting a benefit in patients’ attention using a homeopathic formula preparation. One component of the preparation was potassium phosphate, widely available off the shelf as <it>Kali phos</it> 6x for cognitive problems. The aim of this exploratory trial was to assess the effectiveness of <it>Kali phos</it> 6x for attention problems associated with mental fatigue.</p> <p>Methods</p> <p>We recruited student and staff volunteers (University of York) with self-reported mental fatigue, excluding any using homeopathy or prescribed stimulants, or with a diagnosis of chronic fatigue syndrome. In a triple blind, cross-over, placebo-controlled clinical trial, 86 volunteers were randomized to receive <it>Kali phos</it> 6x or identical placebo 10 minutes before taking a psychological test of attention (Stroop Colour-Word Test). One week later they were crossed over and took the other preparation before repeating the test.</p> <p>Results</p> <p>We found no evidence of a treatment effect in a comparison of <it>Kali phos</it> 6x with placebo (<it>Kali phos</it> minus placebo = −1.1 (95% CI −3.0 to 0.9, P = 0.3) Stroop score units, Cohen effect size = −0.17) even when allowing for a weak period effect with accuracy scores in the second period being higher than those in the first (P = 0.05). We observed a ceiling effect in the Stroop test which undermined our ability to interpret this result.</p> <p>Conclusions</p> <p><it>Kali phos</it> 6x was not found to be effective in reducing mental fatigue. A ceiling effect in our primary outcome measure meant that we could not rule out a type II error. Thorough piloting of an adequate outcome measure could have led to an unequivocal result.</p> <p>Current Controlled Trials</p> <p>ISRCTN16521161</p>
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.